NVO: Harmonic Pattern Signals Potential ReversalNVO: Harmonic Pattern Signals Potential Reversal
Novo Nordisk (NVO) has completed a Bullish Harmonic Pattern, suggesting that a potential reversal phase may already be underway.
If the pattern holds, we could see a short consolidation before a potential rally toward the first target near 53.50, f
Key facts today
Novo Nordisk has launched Wegovy at $349/month for cash payers. Ozempic prices are similar, except the 2 mg dose at $499. New patients can access both drugs for $199/month until March 2026.
Novo Nordisk's CEO confirmed sufficient stock of Wegovy weight-loss pills for a strong launch, addressing past supply issues. U.S. approval for the pill format is expected by year-end.
Hims & Hers has started offering personalized versions of semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, after a government ban on the mass production of copies.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
23.35 DKK
100.99 B DKK
290.40 B DKK
3.17 B
About Novo Nordisk A/S Class B
Sector
Industry
CEO
Maziar Mike Doustdar
Website
Headquarters
Bagsværd
Founded
1923
ISIN
DK0062498333
FIGI
BBG000F8TZ33
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Related stocks
$NVO Short Setup | EMA Wall Stops Bulls, Downside Active🎯 NVO Bearish Breakdown: 200 EMA Rejection Setup 🐻
📊 Asset Overview
Novo Nordisk (NVO) - NYSE
Type: Swing/Day Trade Opportunity
Bias: Bearish Reversal Confirmed ⚠️
🔍 Technical Analysis
The bulls just got rejected harder than a bad pickup line at the 200 EMA! 📉 We're seeing strong bearish momentum
NVO Swing LongFew ways to approach this trade. Look for previous lows at 45 to get taken and look to swing long once back above. More conservative approach would be to wait for a monthly close back above 56.46 as that would confirm a HTF change trend where one should look to buy on pullbacks. If price takes the l
$NVO Last opportunity!🌱 Novo Nordisk: A Healthy Pullback in a Long-Term Growth Story
After years of remarkable growth, Novo Nordisk (NYSE: NVO) has seen its stock cool off — sliding from over 💲130 to around 💲49. At first glance, that might look alarming, but the reality is far more balanced. What we’re seeing is an or
Novo Nordisk selloff an opportunity if markets slumpMarkets are stretched. Tech and AI have run hot. If sentiment breaks, investors will pivot fast. Novo Nordisk offers safety, scale, and cashflow. But this isn’t a flawless story.
Novo’s stock has pulled back. Some of that is market-driven. But part of it is real. Growth expectations were stretched.
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
XS300255582
Novo Nordisk Finance (Netherlands) BV 3.625% 27-MAY-2037Yield to maturity
3.70%
Maturity date
May 27, 2037
N
XS282046075
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2034Yield to maturity
3.43%
Maturity date
May 21, 2034
N
XS300255353
Novo Nordisk Finance (Netherlands) BV 3.125% 27-MAY-2033Yield to maturity
3.27%
Maturity date
May 27, 2033
N
XS282045567
Novo Nordisk Finance (Netherlands) BV 3.25% 21-JAN-2031Yield to maturity
3.04%
Maturity date
Jan 21, 2031
N
XS300255329
Novo Nordisk Finance (Netherlands) BV 2.875% 27-AUG-2030Yield to maturity
2.97%
Maturity date
Aug 27, 2030
XS244124704
Novo Nordisk Finance (Netherlands) BV 1.375% 31-MAR-2030Yield to maturity
2.79%
Maturity date
Mar 31, 2030
N
XS282045460
Novo Nordisk Finance (Netherlands) BV 3.125% 21-JAN-2029Yield to maturity
2.75%
Maturity date
Jan 21, 2029
N
XS300255299
Novo Nordisk Finance (Netherlands) BV 2.375% 27-MAY-2028Yield to maturity
2.72%
Maturity date
May 27, 2028
XS234803042
Novo Nordisk Finance (Netherlands) BV 0.125% 04-JUN-2028Yield to maturity
2.60%
Maturity date
Jun 4, 2028
N
XS282044994
Novo Nordisk Finance (Netherlands) BV 3.375% 21-MAY-2026Yield to maturity
2.49%
Maturity date
May 21, 2026
XS244933017
Novo Nordisk Finance (Netherlands) BV 1.125% 30-SEP-2027Yield to maturity
2.39%
Maturity date
Sep 30, 2027
See all NOVO_B bonds
Curated watchlists where NOVO_B is featured.
Frequently Asked Questions
The current price of NOVO_B is 309.00 DKK — it has decreased by −0.80% in the past 24 hours. Watch Novo Nordisk A/S Class B stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OMXCOP exchange Novo Nordisk A/S Class B stocks are traded under the ticker NOVO_B.
NOVO_B stock has risen by 3.28% compared to the previous week, the month change is a −12.09% fall, over the last year Novo Nordisk A/S Class B has showed a −58.58% decrease.
We've gathered analysts' opinions on Novo Nordisk A/S Class B future price: according to them, NOVO_B price has a max estimate of 540.00 DKK and a min estimate of 270.00 DKK. Watch NOVO_B chart and read a more detailed Novo Nordisk A/S Class B stock forecast: see what analysts think of Novo Nordisk A/S Class B and suggest that you do with its stocks.
NOVO_B reached its all-time high on Jun 26, 2024 with the price of 1,033.20 DKK, and its all-time low was 0.85 DKK and was reached on Mar 28, 1988. View more price dynamics on NOVO_B chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NOVO_B stock is 3.00% volatile and has beta coefficient of 1.58. Track Novo Nordisk A/S Class B stock price on the chart and check out the list of the most volatile stocks — is Novo Nordisk A/S Class B there?
Today Novo Nordisk A/S Class B has the market capitalization of 1.38 T, it has increased by 9.43% over the last week.
Yes, you can track Novo Nordisk A/S Class B financials in yearly and quarterly reports right on TradingView.
Novo Nordisk A/S Class B is going to release the next earnings report on Feb 4, 2026. Keep track of upcoming events with our Earnings Calendar.
NOVO_B earnings for the last quarter are 4.50 DKK per share, whereas the estimation was 4.90 DKK resulting in a −8.11% surprise. The estimated earnings for the next quarter are 6.01 DKK per share. See more details about Novo Nordisk A/S Class B earnings.
Novo Nordisk A/S Class B revenue for the last quarter amounts to 74.98 B DKK, despite the estimated figure of 76.53 B DKK. In the next quarter, revenue is expected to reach 78.66 B DKK.
NOVO_B net income for the last quarter is 20.01 B DKK, while the quarter before that showed 26.50 B DKK of net income which accounts for −24.51% change. Track more Novo Nordisk A/S Class B financial stats to get the full picture.
Novo Nordisk A/S Class B dividend yield was 1.83% in 2024, and payout ratio reached 50.28%. The year before the numbers were 1.35% and 50.35% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 17, 2025, the company has 76.3 K employees. See our rating of the largest employees — is Novo Nordisk A/S Class B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novo Nordisk A/S Class B EBITDA is 156.24 B DKK, and current EBITDA margin is 50.95%. See more stats in Novo Nordisk A/S Class B financial statements.
Like other stocks, NOVO_B shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novo Nordisk A/S Class B stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novo Nordisk A/S Class B technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novo Nordisk A/S Class B stock shows the sell signal. See more of Novo Nordisk A/S Class B technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.











